Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) FCF Margin (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed FCF Margin for 5 consecutive years, with 29444.0% as the latest value for Q3 2025.

  • On a quarterly basis, FCF Margin fell 1992862.0% to 29444.0% in Q3 2025 year-over-year; TTM through Sep 2025 was 3649.57%, a 916636.0% increase, with the full-year FY2023 number at 4130.36%, down 93528.0% from a year prior.
  • FCF Margin was 29444.0% for Q3 2025 at Lyra Therapeutics, down from 3601.09% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 852.38% in Q4 2024 to a low of 110836.36% in Q4 2022.
  • A 5-year average of 16918.36% and a median of 3876.83% in 2023 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: tumbled -10626810bps in 2022, then skyrocketed 9707130bps in 2023.
  • Lyra Therapeutics' FCF Margin stood at 4568.27% in 2021, then plummeted by -2326bps to 110836.36% in 2022, then skyrocketed by 88bps to 13765.07% in 2023, then soared by 106bps to 852.38% in 2024, then plummeted by -3554bps to 29444.0% in 2025.
  • Per Business Quant, the three most recent readings for LYRA's FCF Margin are 29444.0% (Q3 2025), 3601.09% (Q2 2025), and 4831.69% (Q1 2025).